178 related articles for article (PubMed ID: 35241735)
1. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract][Full Text] [Related]
2. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
4. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
6. Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma.
Yao D; Xia S; Jin C; Zhao W; Lan W; Liu Z; Xiu Y
Cell Cycle; 2020 Sep; 19(17):2195-2206. PubMed ID: 32783497
[TBL] [Abstract][Full Text] [Related]
7. miR-155-5p Promotes Cell Proliferation and Migration of Clear Cell Renal Cell Carcinoma by Targeting PEG3.
Wu H; Wu H; Sun P; Zhu D; Ma M; Fan W
Urol Int; 2021; 105(9-10):906-915. PubMed ID: 34192708
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis.
Li W; Li G; Cao L
Bioengineered; 2022 Apr; 13(4):9729-9740. PubMed ID: 35412955
[TBL] [Abstract][Full Text] [Related]
9. MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15.
Deng JH; Zheng GY; Li HZ; Ji ZG
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10699-10707. PubMed ID: 31858538
[TBL] [Abstract][Full Text] [Related]
10. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
13. Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.
Okato A; Arai T; Yamada Y; Sugawara S; Koshizuka K; Fujimura L; Kurozumi A; Kato M; Kojima S; Naya Y; Ichikawa T; Seki N
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902136
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs MiR-15a and MiR-26a cooperatively regulate O-GlcNAc-transferase to control proliferation in clear cell renal cell carcinoma.
Kalantzakos TJ; Sullivan TB; Sebel LE; Canes D; Burks EJ; Moinzadeh A; Rieger-Christ KM
Cancer Biomark; 2021; 30(3):343-351. PubMed ID: 33337348
[TBL] [Abstract][Full Text] [Related]
15. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression.
Wang C; Cai L; Liu J; Wang G; Li H; Wang X; Xu W; Ren M; Feng L; Liu P; Zhang C
Cell Physiol Biochem; 2017; 43(6):2405-2419. PubMed ID: 29073630
[TBL] [Abstract][Full Text] [Related]
17. The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2.
Chen Z; Zhang J; Zhang Z; Feng Z; Wei J; Lu J; Fang Y; Liang Y; Cen J; Pan Y; Huang Y; Zhou F; Chen W; Luo J
Cell Death Dis; 2017 Jun; 8(6):e2859. PubMed ID: 28569782
[TBL] [Abstract][Full Text] [Related]
18. [MiR-744-5p inhibits the proliferation, invasion, and migration of clear-cell renal cell carcinoma cells by targeting CCND1].
Lei K; Xie W; Sun T; Liu Y; Wang X
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):712-717. PubMed ID: 35673915
[TBL] [Abstract][Full Text] [Related]
19. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
20. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.
Arai T; Okato A; Kojima S; Idichi T; Koshizuka K; Kurozumi A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
Cancer Sci; 2017 Oct; 108(10):2088-2101. PubMed ID: 28746769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
